OPEN END TURBO PUT WARRANT - ASTRAZENECA ADR | Real-time Bid/Ask 07:00:55 2024-07-11 am EDT | ||
| 1.29 EUR / 1.31 EUR | -8.45% |
|
| Current month | +12.70% | ||
| 1 month | +27.93% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 1.31 | -7.75% |
| 24-07-10 | 1.42 | +4.41% |
| 24-07-09 | 1.36 | -3.55% |
| 24-07-08 | 1.41 | +6.82% |
| 24-07-05 | 1.32 | -5.04% |
Delayed Quote Börse Stuttgart
Last update July 11, 2024 at 02:27 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | UBS |
| WKN | UM5NK9 |
| ISIN | DE000UM5NK95 |
| Date issued | 2024-05-14 |
| Strike | 91.29 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.31 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.43 € |
|---|---|
| Lowest since issue | 1.01 € |
| Spread | 0.02 € |
| Spread % | 1.53% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
155.1
USD
Average target price
175.3
USD
Spread / Average Target
+13.01%
- Stock Market
- Certificates
- Certificat
